Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Non-animal Alternative Testing Market Projected to Surpass $29,390.3 Million and Grow at 13.48% CAGR During the 2021-2030 Forecast Period [290-Pages] | Acclaimed by Research Dive

This image opens in the lightbox

News provided by

Research Dive

30 Aug, 2022, 12:59 GMT

Share this article

Share toX

Share this article

Share toX

Non-animal alternative testing market predicted to grow by 2030 due to rising chronic diseases among elderly population. Pharmaceutical industry sub-segment to have highest growth rate. Market in the North America region to prosper by 2030.

NEW YORK, Aug. 30, 2022 /PRNewswire/ -- Research Dive has added a new report to its offering titled, 'Non-animal Alternative Testing Market by Technology (Cell Culture Technology, High Throughput Technology, Molecular Imaging, and Omic Technology), Method (Cellular Assay, Biochemical Assay, In Silico, and Ex-vivo), End-user (Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemical Industry, and Food Industry), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2030.'

According to the report, the global non-animal alternative testing market is projected to register a revenue of $29,390.3 million and grow at 13.48% CAGR during the forecast period 2021-2030.

To get access to the All-Inclusive PDF Sample of the Non-animal Alternative Testing Market Click Here!

Dynamics of the Market

Drivers: The high risk of chronic diseases among the millennials, especially the elderly population, along with researchers increasing R&D activities to explore the potential of drug dosing and toxicity are some factors to drive the growth of the global non-animal alternative testing market during the forecast period. Moreover, the growing need for drug development is yet another factor to boost the market growth by 2030.

Opportunities: Strict policies of organizations like PETA and Cruelty-free International that prohibits the torturing or practicing medical examinations or tests on animals along with increasing media campaigns that focus on stopping animal cruelty are some major factors to offer abundant growth opportunities for the global non-animal alternative testing market by 2030. Additionally, rising product portfolio and strategic alliances among market players is also predicted to augment the market development.

Restraints: Lack of awareness about the use of non-animal alternative testing among researchers is the major hindering factor for the market growth.

Covid-19 Impact on the Market

The onset of the Covid-19 pandemic has had a positive impact on the global non-animal alternative testing market due to the surging demand for medicines to strengthen immunity during the deadly times. Many researchers and drug developers restrained from directly operating with animals or humans during pre-clinical trials to curb the spread of the coronavirus that further boosted the market growth. Moreover, the constant need for vaccine development also promoted the alternative methods of testing drugs rather than testing on animals, thus further driving the market growth.

Schedule a call with an Analyst to get Post COVID-19 Impact on Non-animal Alternative Testing Market

Segments of the Market

The report has divided the non-animal alternative testing market into a few segments based on technology, method, end-user, and regional analysis.

  • By technology, the cell culture sub-segment is estimated to hold a dominant market share and gather a revenue of $11,025 million during the 2021-2030 analysis timeframe due to the extensive use of cell culture technology by researchers to assess several test findings. This approach also enables various pharmacological tests to be carried out on eukaryotic cells that have been cultivated under controlled in-vitro environment. This factor is anticipated to bolster the sub-segment's growth by 2030.
  • By method, the ex-vivo sub-segment of the non-animal alternative testing market is expected to have significant growth rate and register a revenue of $3,613.9 million during the analysis years due to cosmetic companies conducting sensitivity tests on cosmetic items to acter to the surging demand for artificial organs in the cosmetics industry. Several human organs are created in-vitro to perform product testing, thus minimizing the usage of animal models and propelling the sub-segment's growth by 2030.
  • By end-user, the pharmaceutical industry sub-segment is predicted to have the highest growth rate and generate a revenue of $13,621.5 million by 2030 due to the expansion of R&D efforts of the pharmaceutical companies to create new medications. Moreover, several encouraging firms are employing in silico drug testing techniques to avoid any type of ethic issues and stop the use of animals for drug testing. These factors are projected to uplift the sub-segment's growth during the analysis years.
  • By region, the non-animal alternative testing market in the North America region is estimated to have the highest growth rate of 12.85% CAGR during the forecast timeframe due to the presence of major non-animal alternative testing companies and their expanding research and development activities for drug testing on artificial human organs. Moreover, rising chronic diseases among the elderly population is also anticipated to boost the market growth in the North America region by 2030.

Request Customization of Non-animal Alternative Testing Market Report & Avail of Amazing Discount

Key Market Players

Some key non-animal alternative testing market players are

  • Hurel Corporation
  • Bio-Rad Laboratories, Inc.
  • Evotec SE
  • MB Research Laboratories
  • TissUse GmbH.
  • VITROCELL Systems GmbH
  • TARA Biosystems, Inc.
  • Abbott
  • Biovit
  • Emulate, Inc.

These players are building several strategies like product development and enhancement, merger and acquisition, partnerships and collaborations to assist the market growth.

For example, in August 2022, the National Institutes of Health, India's medical research agency, announced its strategic plan to cure hepatitis B and improve vaccination strategies by developing new cell culture systems to stop animal-cruelty in the medical field.

The report also sums up various crucial facets including financial performance of the market players, SWOT analysis, product portfolio, and the latest strategic developments.

More about Non-animal Alternative Testing Market:

  • Significance of Non-Animal Alternative Testing Methods
  • Non-animal Alternative Testing Market to Observe Significant Growth Due to Technological Advancements and Company Acquisitions by Market Players, such as CELLINK, SenzaGen AB, and Others

Some Trending Reports:

  • The global anti-blue ray myopia lenses market size was $2,280.80 million in 2021 and is predicted to grow with a CAGR of 7.6%, by generating a revenue of $5,361.10 million by 2030: Access to PDF Sample
  • The global connected drug delivery devices Market share was $290.3 million in 2021 and is predicted to grow with a CAGR of 24.29%, by generating a revenue of $2,095.2 million by 2030: Grab an PDF Sample
  • The global blood stream infection testing market size was $5,173.1 million in 2021 and grow with a CAGR of 8.3%, by generating a revenue of $10,540.8million by 2030: Request PDF Sample

About Research Dive

Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With an unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact:
Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York NY 10005
(P) +91-(788)-802-9103 (India)
+1-(917)-444-1262 (US)
Toll Free: 1-888-961-4454
E-mail: support@researchdive.com 
Website: 
https://www.researchdive.com
Blog: 
https://www.researchdive.com/blog/
LinkedIn: 
https://www.linkedin.com/company/research-dive/
Twitter: 
https://twitter.com/ResearchDive
Facebook: 
https://www.facebook.com/Research-Dive-1385542314927521

Logo: https://mma.prnewswire.com/media/997523/Research_Dive_Logo.jpg  

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.